Experienced in HER2 Negative Breast Cancer

Dr. Elhamy D. Eskander

Oncology | Hematology | Hematology Oncology
Frederick Health Medical Group LLC
194 Thomas Johnson Dr, 
Frederick, MD 
Experienced in HER2 Negative Breast Cancer
Frederick Health Medical Group LLC
194 Thomas Johnson Dr, 
Frederick, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Elhamy Eskander is an Oncologist and a Hematologist in Frederick, Maryland. Dr. Eskander is rated as an Experienced provider by MediFind in the treatment of HER2 Negative Breast Cancer. His top areas of expertise are Lung Cancer, Childhood Iron Deficiency Anemia, Pleuropulmonary Blastoma, and Autoimmune Hemolytic Anemia.

His clinical research consists of participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Hematology Oncology
Licenses
Internal Medicine in MD
Hospital Affiliations
Frederick Health Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

FREDERICK HEALTH MEDICAL GROUP LLC
194 Thomas Johnson Dr, Frederick, MD 21702
Other Locations
FREDERICK HEALTH MEDICAL GROUP LLC
501 W 7th St, Suite 104, Frederick, MD 21701
FREDERICK HEALTH MEDICAL GROUP LLC
141 Thomas Johnson Dr, Suite 200, Frederick, MD 21702
FREDERICK HEALTH MEDICAL GROUP LLC
1562 Opossumtown Pike, Suite 301, Frederick, MD 21702
FREDERICK HEALTH MEDICAL GROUP LLC
400 W 7th St, Frederick, MD 21701
FREDERICK HEALTH MEDICAL GROUP LLC
7211 Bank Ct, Frederick, MD 21703

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: August 26, 2025
Intervention Type: Drug
Study Drugs: Zimberelimab, Domvanalimab, Etrumadenant
Study Phase: Phase 2
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Enrollment Status: Completed
Publish Date: July 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Etoposide, Nivolumab
Study Phase: Phase 2
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 8 Less Clinical Trials
Similar Doctors
Distinguished in HER2 Negative Breast Cancer
Dr. Carol K. Tweed
Oncology | Hematology | Hematology Oncology
Distinguished in HER2 Negative Breast Cancer
Dr. Carol K. Tweed
Oncology | Hematology | Hematology Oncology

Maryland Oncology Hematology PA

11886 Healing Way, 
Silver Spring, MD 
 (36.5 miles away)
301-933-3216
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Carol Tweed is an Oncologist and a Hematologist in Silver Spring, Maryland. Dr. Tweed is rated as a Distinguished provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and HER2 Negative Breast Cancer. Dr. Tweed is currently accepting new patients.

Advanced in HER2 Negative Breast Cancer
Dr. Carolyn B. Hendricks
Hematology Oncology | Oncology
Advanced in HER2 Negative Breast Cancer
Dr. Carolyn B. Hendricks
Hematology Oncology | Oncology

Maryland Oncology Hematology PA

6420 Rockledge Drive, Suite 4200, Suite 4200, 
Bethesda, MD 
 (33.9 miles away)
301-929-0765
Languages Spoken:
English
See accepted insurances

Carolyn Hendricks is a Hematologist Oncology specialist and an Oncologist in Bethesda, Maryland. Dr. Hendricks is rated as a Distinguished provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Triple-Negative Breast Cancer, and HER-2 Positive Breast Cancer. She is board certified in American Board Of Internal Medicine.

Advanced in HER2 Negative Breast Cancer
Dr. Lauren A. Mauro
Oncology | Hematology | Hematology Oncology
Advanced in HER2 Negative Breast Cancer
Dr. Lauren A. Mauro
Oncology | Hematology | Hematology Oncology

Inova Health Care Services

3600 Joseph Siewick Dr, 
Fairfax, VA 
 (39.0 miles away)
703-391-3600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lauren Mauro is an Oncologist and a Hematologist in Fairfax, Virginia. Dr. Mauro is rated as a Distinguished provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Inflammatory Breast Cancer. Dr. Mauro is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Eskander's expertise for a condition
ConditionClose
    View All 40 Advanced Conditions
    View All 135 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile